Background. Children who sustain traumatic brain injury (TBI) are at risk for developing hypopituitarism, of which growth hormone deficiency (GHD) is the most common manifestation. Objective. To determine the prevalence of GHD and associated features following TBI among children and adolescents. Study design. A total of 32 children and adolescents were recruited from a pediatric TBI clinic. Participants were diagnosed with GHD based on insufficient growth hormone release during both spontaneous overnight testing and following arginine/glucagon administration. Results. GHD was diagnosed in 5/32 participants (16%). Those with GHD exhibited more rapid weight gain following injury than those without GHD and had lower levels of free thyroxine and follicle-stimulating hormone. Males with GHD had lower testosterone levels. Conclusions. GHD following TBI is common in children and adolescents, underscoring the importance of assessing for GHD, including evaluating height and weight velocities after TBI. Children and adolescents with GHD may further exhibit absence or intermediate function for other pituitary hormones.
Introduction
Traumatic brain injury (TBI) affects a growing number of pediatric patients, with an incidence of at least 180 to 250 per 100 000 children each year and with infants/toddlers and adolescents being the most commonly affected. 1, 2 Abnormalities of pituitary function have been recognized for many years in adult survivors of TBI [3] [4] [5] [6] [7] but have only recently been reported in children and adolescents in case reports and case series. [8] [9] [10] Among abnormalities in pituitary function after TBI in children, growth hormone deficiency (GHD) appears to be the most common. [8] [9] [10] GHD may affect not only linear growth, but it has also been implicated in lipid abnormalities and body composition changes in children and adolescents [11] [12] [13] [14] and associated with cognitive impairments and poor recovery from TBI. [15] [16] [17] [18] [19] Knowledge of the associated features of GHD after TBI in children and adolescents may improve the ability for treating physicians to recognize and refer patients suspected of having pituitary abnormalities, especially GHD.
To date, there have been no prospective studies that we are aware of that assess for GHD in children and adolescents who have sustained a TBI. Therefore, our goal was to determine the prevalence of GHD and its associated clinical factors among a group of children and adolescents following TBI.
Methods
This study was approved by the institutional review board of the University of Virginia. All children and adolescents aged 8 to 21 years evaluated at Kluge Children's Rehabilitation Center (KCRC) brain injury clinic from November 21, 2007, to June 1, 2009, who had a history of moderate-to-severe TBI were offered the opportunity to participate in the study by the attending physician, if they met the predetermined criteria. Moderate-to-severe TBI was defined as a Glasgow Coma Scale (GCS) score ≤ 13 or, in the absence of a GCS score, by a history suggestive that the GCS was in the target range combined with abnormal findings on brain MRI related to the injury. Inclusion criteria also specified freedom from medications or endocrine treatments that would affect GH and Insulin like growth factor 1 (IGF-1) levels.
After appropriate consent was obtained, preinjury height, weight, and BMI were determined by record review and/or parental history. Puberty stage was assessed and recorded as described by Tanner. The study participants were admitted to the University of Virginia General Clinical Research Center (UVA GCRC) for overnight blood sampling for GH concentrations during which an IV catheter was placed, and blood samples were drawn every 20 minutes from 20:00 to 08:00 hours. In the morning, laboratory studies were obtained, including IGF-1, IGFBP-3, cortisol, insulin, free T4, thyroid-stimulating hormone (TSH), estradiol, DHEA-S (dehydroepiandrosterone sulfate), testosterone, prolactin, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). An arginine/ glucagon GH stimulation test was then administered, using 0.5 g/kg of 10% arginine hydrochloride IV (maximum dose 20 g) and 0.02 mg/kg of glucagon Subcutaneous (SC). GHD was diagnosed based on the presence of both a peak serum GH level on overnight testing of <5 ng/ mL 20,21 and a peak GH level following arginine/glucagon of <7 ng/mL for those <18 years or <5 ng/mL for those ≥18 years. 3, 22, 23 Those who did not secrete GH above these levels but had exhibited spontaneous GH release above these cutoff limits ≤1 hour prior to the arginine/ glucagon stimulation test were considered to have adequate GH reserve and were not classified as having GHD. The cutoff level for overnight testing was chosen based on results from overnight sampling in healthy children, 20, 21 whereas the provocative testing cutoff was based on recommendations of international endocrine societies, adjusting for alterations in GH measurement using monoclonal antibody techniques. 22, 23 The cutoff for adolescents ≥18 years was based on standards for diagnosing adult GHD. 3 Laboratory samples were stored at -80°C and tested at the Core Laboratory of the UVA General Clinical Research Center using 2-site chemiluminescence immunoassays on an Immulite 2000 (Diagnostic Products Corporation, Los Angeles, CA), according to the manufacturer's specifications. For GH, the assay range is 0.05 to 40 ng/mL. Intraassay/interassay coefficients of variation for samples tested in this laboratory are as follows: growth hormone, 3.3%/6.4%; IGF-1, 2.8%/5.6%; free T4, 4.7%/7.1%; TSH, 3.9%/7.6%; LH, 4.2%/6.2%; FSH, 4.5%/6.8%; testosterone, 6.8%/9.6%; estradiol, 7.0%/5.4%; prolactin, 2.1%/5.8%; DHEA-S, 6.0%/7.4%.
All analyses used SAS Version 9.1 (SAS Institute Inc, Cary, NC). Standardized measures were computed with respect to gender and age in the form of z scores. BMI z scores were calculated from CDC reference values, and z scores for IGF-1 were computed based on age-based references for the Immulite. Those found to have GHD were compared with those who did not have GHD with respect to a number of factors. Comparisons based on continuous outcomes were made using the Mann-Whitney test with corresponding exact P values; rates of categorical outcomes were compared via Fisher's exact test. Spearman correlations were computed to assess associations between GH levels and BMI z score as well as injury severity (as indexed by GCS).
Results
Among the families of patients from the TBI clinic who were eligible to enroll in the study, 32/52 (62%) elected to participate. Enrollees did not differ from those who declined to participate in the following characteristics: proportion male, age at injury, age at prospective enrollment, GCS (data not shown).
Among the participants, 6/32 did not have an overnight GH level above 5 ng/mL, and 10/32 did not have GH levels above 7 ng/mL (participants <18 years) or 5 ng/mL (participants ≥18 years) in response to provocative stimuli. GHD was diagnosed in 5/32 (16%) who failed both testing modalities, whereas an additional 19% (6/32) exhibited insufficient GH secretion during 1 of the 2 tests.
Those with GHD had lower spontaneous GH release overnight (P < .001; Figure 1 ), lower integrated overnight GH release (area under the curve; P < .001), lower peak GH on provocative testing (P < .001), and lower GH area under the curve during provocative testing (P < .001; Table 1 ). There was no significant difference in IGF-1 z scores between the 2 groups; 3/5 participants with GHD and 3/27 without GHD had IGF-1 z scores >2 standard deviations below the mean for age (not significant [NS]; Table 1 ).
Characteristics and additional laboratory values of those with GHD compared with those without GHD are shown in Table 1 . In addition to these characteristics, 1 person (with GHD) had diabetes insipidus. Compared with those without GHD, those with GHD were older at time of injury and had a shorter interval between injury and testing. Regarding other pituitary hormones, those with GHD had lower free T4 values than those without GHD (P < .05), though only 1 of these participants had a frankly low free T4 (data not shown). There was no difference in TSH concentration between the groups. Morning cortisol levels for those with GHD was 5.8 ± 1.7 mg/dL compared with 10.1 ± 1.0 mg/dL for those without GHD (NS); morning cortisol was <5 mg/dL in 3/5 participants with GHD compared with 3/27 without GHD (NS; data not shown). Among those at Tanner 3 to 5, FSH levels were lower in those with GHD (P < .05), and males with GHD had a lower testosterone level (P < .05). There were no differences in LH or estradiol concentrations (girls Tanner 3-5: GHD 49.0, n = 1; no GHD 50.5 ± 19.5, n = 11; P = 1.0). Although not statistically significant (P = .0833), those with GHD had a higher mean BMI z score (Table  1 and Figure 2A ). Those with GHD were more likely to gain weight excessively in the interval between injury and GH stimulation testing ( Table 1 and Figure 2B ; P = .02). Given that all the participants in the GHD group were ≥15 years and thus would not have the same growth potential as younger participants, weight gain was compared between those with GHD and those without GHD who were ≥15 years. Weight gain was still significantly greater for those with GHD (P = .02), with older individuals without GHD gaining virtually no weight (mean = 0.8 kg/year). Regarding severity of injury, there was no significant difference in GCS following injury between those with or without GHD (Table 1 ).
Discussion
TBI is a serious cause of morbidity and mortality in children and adolescents and is increasingly recognized as a cause of pituitary dysfunction in this population. Previous prospective investigations in adults and retrospective investigations in children and adolescents have identified GHD as the most common anterior pituitary deficit following TBI. 3, 6, [8] [9] [10] 17 GHD is an important issue for pediatric health care providers to recognize in TBI patients because of its potential effects on recovery from TBI, future growth, attainment of adult body composition, [12] [13] [14] neurocognitive function, 15, 17, 18 and quality of life 15deficits that may improve following treatment with human GH. 24 Thus far, case reports and case series have suggested that GHD after TBI in children and adolescents may be underrecognized. [8] [9] [10] In the current study of 32 children and adolescents with a history of moderate to severe TBI, 15% (5/32) exhibited clear GHD, including low GH response to stimulation testing and low spontaneous peak GH values during overnight testing. An additional 19% (6/32) had an abnormal response in one or the other of these tests, such that of 34% (11/32) of children and adolescents exhibited some laboratory abnormalities suggestive of diminished GH function. The participants who exhibited an abnormal response on only 1 of the 2 tests may represent individuals at a less-severe place on the spectrum of GHD or may merely reflect the imperfect nature of these tests. These prevalence rates in the current study compare with a rate of 42% of GHD following TBI in the largest cross-sectional study following TBI in children, which used provocative stimulation on 26 children and adolescents as their sole assessment of GH sufficiency. 9 Among adults who have suffered TBI, 15% to 28% are reported to have GHD. 3, 15 The most notable effect of GH action in children relates to linear growth. Height velocity was difficult to evaluate in our cohort because of poor records regarding preinjury heights and because many participants were past the age of expected epiphyseal fusion. All our participants with GHD were >15.5 years at the time of injury and would not have been expected to have much growth potential. Nevertheless, height velocity remains an important parameter to follow prospectively in younger children after TBI because it may be the first indication of GHD.
Our participants with clear GHD exhibited more rapid weight gain in the interval between injury and testing. Indeed, whereas only 2 of the participants with GHD were overweight at the time of injury, as a group, they gained an average of 25 kg/year following their TBI. These observations are consistent with data from studies in adults 3, 15 and with our understanding of the effects of GHD on body composition and weight gain. 13, 25 In Figure 2 . Body weight and GHD: A. BMI z score was not different between those with GHD and those without GHD (P > .05). B. Those with GHD were more likely to gain weight between injury and time of stimulation testing addition, rapid weight gain has been noted after injury to the hypothalamus. 26 Obesity is associated with lower GH secretion and may make the definition of true GHD more difficult. 20 Those with GHD had a significantly lower interval between injury and testing compared with those without GHD. Prior studies in adults have shown stable levels of GHD among those tested at 3 months and at 6 to 9 months after injury. 6, 15 All our participants but one with GHD were tested at least 6 months following injury.
Those with GHD tended to have low levels of IGF-1 (z score = -2.05 ± 0.53), though these levels were not significantly lower than those in participants without GHD (z score = -1.42 ± 0.32). This finding is in keeping with data in adults suggesting that IGF-1 levels are not a reliable way to identify GHD following TBI, in that only 17% to 30% of adults with GHD had a low IGF-1 level. 3, 19 Although our study was designed to detect differences in GH and not other pituitary hormones, we did test the integrity of other hormone axes. Among those at Tanner 3 to 5 development, individuals with GHD had lower FSH levels (but similar LH levels) compared with those without GHD, and males with GHD had lower testosterone levels. Though our participants with GHD did not have pathologically low testosterone levels, the decrease in testosterone may reflect a decrease in gonadotropindriven testosterone production. These data are in keeping with prior reports in adults demonstrating gonadotropin deficiency to be the second most common pituitary defect following TBI. 3, 15, 17 Participants with GHD in our study had lower free T4 levels but similar TSH levels as compared with those without GHD, though only 1 of the participants with GHD had a free T4 value below the normal range. The lower levels of free T4 may imply a decrease in TSH secretion to drive thyroxine production. Similarly, those with GHD tended toward lower morning cortisol values, with 3/5 participants with GHD having a cortisol level <5 mg/dL compared with 3/27 without GHD. These findings serve as a reminder that patients who had TBI are at risk for multiple pituitary deficiencies besides GHD and that treating physicians should have a high index of suspicion for the presence of pituitary deficiencies for months to years postinjury. 15 There has been much debate regarding the mechanism determining hypopituitarism in those with TBI. Injury to the hypothalamus and/or pituitary gland has been commonly thought to be because of shearing forces and hemorrhage. Initial GCS continues to be commonly used to determine the severity of TBI. There have been conflicting reports in adults regarding the ability of initial GCS to predict the risk of later pituitary deficiency, with studies reporting positive correlation 27, 28 or no relationship. 3, 17, 29 We did not find a difference in GCS between those with and without GHD and would submit that close follow-up for signs of pituitary deficiencywith particular attention to growth and adolescent development-is important after any TBI, regardless of its severity. Children with suspected pituitary findings, including suspected GHD, should be referred for further evaluation.
In conclusion, our results support recent observations that pituitary dysfunction-and particularly GHD-after TBI is more common in children and adolescents than previously concluded. Given this high prevalence, pediatricians who care for children after TBI should monitor for growth and excessive weight gain following TBI and have a low threshold to refer for suspected GHD or other pituitary abnormalities. 30 Our results emphasize the need for larger, prospective studies in this population. A better understanding of the prevalence of GHD and other pituitary abnormalities after childhood TBI is likely to improve the medical management of these children and result in improved recovery from TBI.
